This bill changes Medicare billing rules for remote monitoring services, allowing providers to bill for a minimum of 2 days of patient data collected over a 30-day period instead of the current 16 days. It directly affects Medicare patients with chronic conditions (like diabetes, heart failure, or post-surgery recovery) and healthcare providers who use remote monitoring tools. The key provision eliminates the 16-day requirement for all patients - not just during the pandemic - based on clinical evidence showing shorter monitoring periods are sufficient for many conditions. The bill also requires a report to Congress within one year analyzing the impact and recommending future reimbursement models. This aims to reduce administrative barriers while maintaining coverage for clinically appropriate remote monitoring.
This bill requires public schools receiving federal education funds to implement concussion safety protocols. Schools must develop plans including staff training, visible posting of evidence-based concussion information, immediate removal from activities if a concussion is suspected, and written medical clearance before returning to sports. It also mandates academic accommodations like modified assignments and cognitive rest during recovery, applying to all students regardless of where a concussion occurred. States failing to comply face reduced federal education funding (5% the first year, 10% thereafter). The law directly affects public school students, athletes, and school staff across all grade levels.
This bill reauthorizes and expands federal programs addressing the opioid crisis and related health issues through 2030, with increased funding for prevention, treatment, and recovery services. It provides specific funding increases for programs including prenatal and postnatal health services, fetal alcohol spectrum disorder prevention, first responder training, and community-based recovery centers. Key provisions include enhanced cybersecurity protections for suicide prevention hotlines, requirements for reporting on program effectiveness, and expanded support for individuals with substance use disorders through workforce development and peer support services. The bill directly affects healthcare providers, public health agencies, community organizations, and individuals seeking treatment for substance use disorders.
S 1074, the *Agricultural Access to Substance Use Disorder Treatment and Mental Health Care Act of 2025*, mandates a study on mental health and substance use disorder care access for farmers, ranchers, and agricultural workers. The Comptroller General will examine rural availability of specialized providers, barriers like cost or geography, and effective programs (such as telehealth or cultural training) to inform future policy. The study’s findings will be submitted to key congressional committees and federal agencies, including Agriculture and Health and Human Services, to guide potential improvements in care accessibility for agricultural communities. This procedural bill does not create new programs but focuses on gathering data to address existing gaps.
This bill defines "copy-cat ingredients" as substances mimicking approved drugs but made via different processes or with lower quality, and clarifies "counterfeit drugs" under existing law. It updates the Fentanyl Sanctions Act to replace all references to "opioid" with "illicit drug," expanding the law's scope to cover all counterfeit pharmaceuticals - not just opioid-related products. The bill also adds a waiver allowing access to medications on the HHS drug shortage list. These changes help regulators and law enforcement better identify and address counterfeit drugs affecting patients and the healthcare system.
The TREATS Act amends the Controlled Substances Act to allow telehealth evaluations as an alternative to in-person medical evaluations for prescribing certain controlled substances. Specifically, it permits one telehealth evaluation (conducted via real-time audio/video systems meeting Social Security Act standards) instead of an in-person visit when prescribing FDA-approved medications for substance use disorder treatment (schedules III-V). This directly affects healthcare providers who prescribe these medications, expanding their ability to use telehealth for initial patient assessments. The change maintains the requirement for at least one evaluation (either in-person or telehealth) while updating the process to include telehealth options for this specific treatment context.
S 3209, the NOPAIN for Veterans Act, requires the Department of Veterans Affairs (VA) to include non-opioid pain medications in its national formulary for veterans. The bill defines "non-opioid pain management drugs" as FDA-approved treatments for acute pain that don't use opioid receptors. The VA must add these drugs within one year of FDA approval or eligibility for payment under federal health programs, whichever comes first. This policy change directly affects veterans receiving VA pain management care by expanding access to non-opioid options, while prohibiting use of the Cost of War Toxic Exposures Fund to implement this provision.
The PEERS Act of 2025 requires Medicare to cover peer support services provided by certified specialists at community mental health centers, rural health clinics, and other specified facilities. It directly affects Medicare beneficiaries with mental health or substance use disorders who receive these services, and providers like community mental health centers that will now bill Medicare for this care. The bill defines peer support services as non-clinical assistance focused on recovery, community integration, and self-empowerment, delivered by individuals certified after recovering from similar conditions. Coverage begins January 1, 2027.
The Treatment Court, Rehabilitation, and Recovery Act of 2025 creates a federal grant program to fund specialized courts addressing substance use disorders. It provides funding for juvenile drug courts, family treatment courts, tribal healing courts, impaired driving courts, and adult drug courts that meet national standards. The bill requires evidence-based treatment - including medication-assisted treatment - and prohibits discrimination based on race, gender, or other protected characteristics. Eligible participants must have a diagnosed substance use disorder, meet safety criteria, and demonstrate potential benefit from the program, with costs based on ability to pay. The program mandates annual reporting on outcomes and ensures grants cover up to 75% of program costs, administered through the Department of Justice.
The Comprehensive Addiction and Recovery Justice Grant Reauthorization Act (S 2540) extends federal funding for state and local programs that provide addiction treatment and recovery services to individuals involved in the justice system, such as those in courts or correctional facilities. It updates the authorization period from 2019-2023 to 2026-2030, ensuring continued support through 2030 without altering annual funding amounts. This reauthorization directly affects state and local agencies administering these grants, which help connect people with substance use disorders to treatment while navigating legal processes. The bill does not specify new funding levels but secures program continuity by extending the timeframe for grant distribution.
